Aveo shares get a boost from the ‘Idenix effect’

More that a year after the high-profile FDA rejection that dashed the hopes of Aveo Pharmaceuticals to be the next commercial-stage cancer drug company in Massachusetts, some investors are starting to take a second look in the past couple weeks thanks in part to the sale of Idenix Pharmaceuticals...